May 21, 2014 07:00 AM Eastern Daylight Time
EuroPCR 2014
SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that the successful live case demonstration of its breakthrough DESolve® 100 Novolimus Eluting Bioresorbable Coronary Scaffold System was presented at the "Multivessel PCI: Whats's new?" session at EuroPCR in Paris. EuroPCR is the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions.
"The patient that I treated during this live demonstration presented a case of complex multi-vessel disease with high degree of calcification. Elixir's DESolve 100 had excellent deliverability, trackability and conformability that enabled me to treat the diseased artery with confidence," said Dr. Stefan Verheye, M.D., Ph.D., ZNA Middleheim Hospital, Antwerp, Belgium, who performed the live case demonstration of the DESolve 100 in his cardiac catherization lab in Belgium that was streamed live to a packed audience in Theater Bleu at EuroPCR. "I'm pleased to report that the acute outcome of the procedure was successful, and the patient is doing well."
Elixir Medical recently announced CE Mark approval for DESolve 100, the world's first fully bioresorbable scaffold with a dramatically thinner strut profile of 100µm (one hundred microns), which is designed to degrade within one year, returning the patients' coronary vessel ultimately to its normal de novo state while providing market-leading deliverability and conformability. DESolve 100 is designed to make scaffolds more user-friendly, enabling cardiologists to address the needs of a broader patient population.
"The successful live case demonstration of Elixir's DESolve 100 at EuroPCR reinforces our commitment of providing cardiologists with the world's first fully bioresorbable scaffold that matches the thin strut profile, excellent deliverability, and enhanced conformability of market-leading coronary drug eluting stents to ensure its greater adoption in everyday clinical practice," said Motasim Sirhan, Chief Executive Officer of Elixir Medical. "Elixir is proud to present the world's broadest portfolio of coronary scaffolds that will help physicians realize their goal of treating and returning the patient's coronary arteries to their de novo state within one year."
Like the CE Marked and clinically-proven DESolve scaffold, DESolve 100 is developed from the same proprietary poly-L Lactide (PLLA)-based material that provides optimal strength and support to the artery while delivering the novel anti-proliferative drug, Novolimus. The unique attributes of the DESolve family of scaffolds include (a) the ability to self-appose to the nominal vessel wall size in cases of mal-apposition; (b) the ability to maintain radial strength and vessel support for the necessary period of vessel healing while degrading within a year; and (c) the ability to have a wide margin of expansion.
About Elixir Medical
Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com
Contacts
For Elixir Medical Corporation
Vinayak Bhat, Ph.D., 408-636-2006